{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T14:01:50Z","timestamp":1784210510613,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,6,11]],"date-time":"2023-06-11T00:00:00Z","timestamp":1686441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,11]],"date-time":"2023-06-11T00:00:00Z","timestamp":1686441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA086862"],"award-info":[{"award-number":["P30CA086862"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1245\/s10434-023-13701-2","type":"journal-article","created":{"date-parts":[[2023,6,11]],"date-time":"2023-06-11T22:01:31Z","timestamp":1686520891000},"page":"6652-6660","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Peritoneal Cell-Free Tumor DNA is a Biomarker of Locoregional and Peritoneal Recurrence in Resected Pancreatic Ductal Adenocarcinomas"],"prefix":"10.1245","volume":"30","author":[{"given":"Katie M.","family":"Leick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Tomanek-Chalkley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen L.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos H. F.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,11]]},"reference":[{"issue":"1","key":"13701_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7\u201333.","journal-title":"CA Cancer J Clin."},{"issue":"1","key":"13701_CR2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.annonc.2022.09.161","volume":"34","author":"T Seufferlein","year":"2022","unstructured":"Seufferlein T, Uhl W, Kornmann M, et al. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX) - a randomized phase II trial of the AIO pancreatic cancer group. Ann Oncol. 2022;34(1):91\u2013100.","journal-title":"Ann Oncol."},{"issue":"3","key":"13701_CR3","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.surg.2015.09.018","volume":"159","author":"KK Christians","year":"2016","unstructured":"Christians KK, Heimler JW, George B, et al. Survival of patients with resectable pancreatic cancer who received neoadjuvant therapy. Surgery. 2016;159(3):893\u2013900.","journal-title":"Surgery."},{"issue":"25","key":"13701_CR4","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","volume":"379","author":"T Conroy","year":"2018","unstructured":"Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395\u2013406.","journal-title":"N Engl J Med."},{"issue":"29","key":"13701_CR5","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1200\/JCO.2017.72.6463","volume":"35","author":"M Sinn","year":"2017","unstructured":"Sinn M, Bahra M, Liersch T, et al. CONKO-005: adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after R0 resection of pancreatic cancer: a multicenter randomized phase III trial. J Clin Oncol. 2017;35(29):3330\u20137.","journal-title":"J Clin Oncol."},{"issue":"4","key":"13701_CR6","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jamcollsurg.2015.12.031","volume":"222","author":"AA Parikh","year":"2016","unstructured":"Parikh AA, Maiga A, Bentrem D, et al. Adjuvant therapy in pancreas cancer: does it influence patterns of recurrence? J Am Coll Surg. 2016;222(4):448\u201356.","journal-title":"J Am Coll Surg."},{"issue":"1","key":"13701_CR7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/01.mpa.0000166998.04266.88","volume":"31","author":"K Shibata","year":"2005","unstructured":"Shibata K, Matsumoto T, Yada K, Sasaki A, Ohta M, Kitano S. Factors predicting recurrence after resection of pancreatic ductal carcinoma. Pancreas. 2005;31(1):69\u201373.","journal-title":"Pancreas."},{"issue":"134","key":"13701_CR8","first-page":"1756","volume":"61","author":"M Suenaga","year":"2014","unstructured":"Suenaga M, Fujii T, Kanda M, et al. Pattern of first recurrent lesions in pancreatic cancer: hepatic relapse is associated with dismal prognosis and portal vein invasion. Hepatogastroenterology. 2014;61(134):1756\u201361.","journal-title":"Hepatogastroenterology."},{"issue":"5","key":"13701_CR9","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1097\/SLA.0000000000002234","volume":"267","author":"VP Groot","year":"2018","unstructured":"Groot VP, Rezaee N, Wu W, et al. Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma. Ann Surg. 2018;267(5):936\u201345.","journal-title":"Ann Surg."},{"issue":"9","key":"13701_CR10","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1016\/j.ejso.2019.04.007","volume":"45","author":"VP Groot","year":"2019","unstructured":"Groot VP, Blair AB, Gemenetzis G, et al. Recurrence after neoadjuvant therapy and resection of borderline resectable and locally advanced pancreatic cancer. Eur J Surg Oncol. 2019;45(9):1674\u201383.","journal-title":"Eur J Surg Oncol."},{"issue":"10","key":"13701_CR11","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1016\/j.ejso.2019.05.031","volume":"45","author":"LA Daamen","year":"2019","unstructured":"Daamen LA, Groot VP, Intven MPW, et al. Postoperative surveillance of pancreatic cancer patients. Eur J Surg Oncol. 2019;45(10):1770\u20137.","journal-title":"Eur J Surg Oncol."},{"issue":"6","key":"13701_CR12","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/0277-5379(87)90266-5","volume":"23","author":"M Stroun","year":"1987","unstructured":"Stroun M, Anker P, Lyautey J, Lederrey C, Maurice PA. Isolation and characterization of DNA from the plasma of cancer patients. Eur J Cancer Clin Oncol. 1987;23(6):707\u201312.","journal-title":"Eur J Cancer Clin Oncol."},{"issue":"9","key":"13701_CR13","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/nm.1789","volume":"14","author":"F Diehl","year":"2008","unstructured":"Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985\u201390.","journal-title":"Nat Med."},{"issue":"6","key":"13701_CR14","doi-asserted-by":"publisher","first-page":"14122","DOI":"10.3390\/ijms160614122","volume":"16","author":"G Francis","year":"2015","unstructured":"Francis G, Stein S. Circulating Cell-Free Tumour DNA in the Management of Cancer. Int J Mol Sci. 2015;16(6):14122\u201342.","journal-title":"Int J Mol Sci."},{"key":"13701_CR15","doi-asserted-by":"crossref","unstructured":"Hata T, Mizuma M, Motoi F, et al. (2022) Prognostic impact of postoperative circulating tumor DNA as a molecular minimal residual disease marker in patients with pancreatic cancer undergoing surgical resection. J Hepatobiliary Pancreat Sci.","DOI":"10.1002\/jhbp.1282"},{"key":"13701_CR16","doi-asserted-by":"publisher","first-page":"902177","DOI":"10.3389\/fonc.2022.902177","volume":"12","author":"P Kirchweger","year":"2022","unstructured":"Kirchweger P, Kupferthaler A, Burghofer J, et al. Prediction of response to systemic treatment by kinetics of circulating tumor DNA in metastatic pancreatic cancer. Front Oncol. 2022;12:902177.","journal-title":"Front Oncol."},{"key":"13701_CR17","doi-asserted-by":"publisher","first-page":"e2200060","DOI":"10.1200\/PO.22.00060","volume":"6","author":"WJ Chapin","year":"2022","unstructured":"Chapin WJ, Till JE, Hwang WT, et al. Multianalyte prognostic signature including circulating tumor DNA and circulating tumor cells in patients with advanced pancreatic adenocarcinoma. JCO Precis Oncol. 2022;6:e2200060.","journal-title":"JCO Precis Oncol."},{"issue":"3","key":"13701_CR18","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41416-021-01624-2","volume":"126","author":"D Pietrasz","year":"2022","unstructured":"Pietrasz D, Wang-Renault S, Taieb J, et al. Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials. Br J Cancer. 2022;126(3):440\u20138.","journal-title":"Br J Cancer."},{"key":"13701_CR19","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1245\/s10434-022-12399-y","volume":"1","author":"BG Sullivan","year":"2022","unstructured":"Sullivan BG, Lo A, Yu J, et al. Circulating tumor DNA is unreliable to detect somatic gene alterations in gastrointestinal peritoneal carcinomatosis. Ann Surg Oncol. 2022;1:278\u201384. https:\/\/doi.org\/10.1245\/s10434-022-12399-y","journal-title":"Ann Surg Oncol."},{"issue":"13","key":"13701_CR20","doi-asserted-by":"publisher","first-page":"5065","DOI":"10.1245\/s10434-020-08832-9","volume":"27","author":"KM Leick","year":"2020","unstructured":"Leick KM, Kazarian AG, Rajput M, et al. Peritoneal cell-free tumor DNA as biomarker for peritoneal surface malignancies. Ann Surg Oncol. 2020;27(13):5065\u201371. https:\/\/doi.org\/10.1245\/s10434-020-08832-9","journal-title":"Ann Surg Oncol."},{"issue":"4","key":"13701_CR21","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1245\/s10434-021-10997-w","volume":"29","author":"K Chiba","year":"2022","unstructured":"Chiba K, Hata T, Mizuma M, et al. Impact of tumor-derived DNA testing in peritoneal lavage of pancreatic cancer patients with and without occult intra-abdominal metastases. Ann Surg Oncol. 2022;29(4):2685\u201397.https:\/\/doi.org\/10.1245\/s10434-021-10997-w","journal-title":"Ann Surg Oncol."},{"key":"13701_CR22","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41575-019-0245-4","volume":"3","author":"L Buscail","year":"2020","unstructured":"Buscail L, Bournet B, Cordelier P. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2020;3:153\u201368.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"5","key":"13701_CR23","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1634\/theoncologist.2017-0467","volume":"23","author":"R Perets","year":"2018","unstructured":"Perets R, Greenberg O, Shentzer T, et al. Mutant KRAS circulating tumor DNA Is an accurate tool for pancreatic cancer monitoring. Oncologist. 2018;23(5):566\u201372.","journal-title":"Oncologist."},{"issue":"1","key":"13701_CR24","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/bjc.2016.175","volume":"115","author":"N Hadano","year":"2016","unstructured":"Hadano N, Murakami Y, Uemura K, et al. Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer. Br J Cancer. 2016;115(1):59\u201365.","journal-title":"Br J Cancer."},{"issue":"8","key":"13701_CR25","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1245\/s10434-018-6561-z","volume":"25","author":"JM Baumgartner","year":"2018","unstructured":"Baumgartner JM, Raymond VM, Lanman RB, et al. Preoperative circulating tumor DNA in patients with peritoneal carcinomatosis is an independent predictor of progression-free survival. Ann Surg Oncol. 2018;25(8):2400\u20138. https:\/\/doi.org\/10.1245\/s10434-018-6561-z","journal-title":"Ann Surg Oncol."},{"issue":"21\u201322","key":"13701_CR26","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/j.cca.2010.07.032","volume":"411","author":"K Jung","year":"2010","unstructured":"Jung K, Fleischhacker M, Rabien A. Cell-free DNA in the blood as a solid tumor biomarker\u2013a critical appraisal of the literature. Clin Chim Acta. 2010;411(21\u201322):1611\u201324.","journal-title":"Clin Chim Acta."},{"issue":"2","key":"13701_CR27","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.pan.2016.12.011","volume":"17","author":"S Ako","year":"2017","unstructured":"Ako S, Nouso K, Kinugasa H, et al. Utility of serum DNA as a marker for KRAS mutations in pancreatic cancer tissue. Pancreatology. 2017;17(2):285\u201390.","journal-title":"Pancreatology."},{"issue":"3 Pt 1","key":"13701_CR28","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.ajog.2005.01.054","volume":"193","author":"EM Swisher","year":"2005","unstructured":"Swisher EM, Wollan M, Mahtani SM, et al. Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer. Am J Obstet Gynecol. 2005;193(3 Pt 1):662\u20137.","journal-title":"Am J Obstet Gynecol."},{"issue":"Suppl 3","key":"13701_CR29","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/s00292-019-00698-3","volume":"40","author":"A Haupts","year":"2019","unstructured":"Haupts A, Roth W, Hartmann N. Liquid biopsy in colorectal cancer\u202f: An overview of ctDNA analysis in tumour diagnostics. Pathologe. 2019;40(Suppl 3):244\u201351.","journal-title":"Pathologe."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-13701-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-023-13701-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-13701-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T14:02:49Z","timestamp":1695045769000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-023-13701-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,11]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["13701"],"URL":"https:\/\/doi.org\/10.1245\/s10434-023-13701-2","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,11]]},"assertion":[{"value":"6 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.H.F.C. received research support from Checkmate Pharmaceuticals, Angiodynamics, and Optimum Therapeutics for clinical trials and research projects unrelated to this study. The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}